Vertex Pharmaceuticals Stock Buy Hold or Sell Recommendation
| VRTX Stock | USD 400.76 4.15 1.02% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Vertex Pharmaceuticals is 'Hold'. Macroaxis provides Vertex Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VRTX positions. The advice algorithm takes into account all of Vertex Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Vertex Pharmaceuticals' buy or sell advice are summarized below:
Real Value 364.42 | Target Price 388.67 | Hype Value 404.91 | Market Value 400.76 | Naive Value 400.15 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Vertex Pharmaceuticals given historical horizon and risk tolerance towards Vertex Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Vertex Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Vertex |
Execute Vertex Pharmaceuticals Buy or Sell Advice
The Vertex recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vertex Pharmaceuticals. Macroaxis does not own or have any residual interests in Vertex Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vertex Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Vertex Pharmaceuticals Trading Alerts and Improvement Suggestions
| Vertex Pharmaceuticals generated a negative expected return over the last 90 days | |
| Vertex Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 97.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Global Diabetes Drugs Market to Witness an Upsurge in Growth by 2030, Examines DelveInsight Key Companies in the Market - Sanofi, AstraZeneca, Pfizer, Johnson Johnson, Novartis, Merck Co., Novo Nordisk, Eli Lilly and Company, Biocon |
Vertex Pharmaceuticals Returns Distribution Density
The distribution of Vertex Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Vertex Pharmaceuticals' future price movements. The chart of the probability distribution of Vertex Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Vertex Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vertex Pharmaceuticals returns is essential to provide solid investment advice for Vertex Pharmaceuticals.
| Mean Return | -0.1 | Value At Risk | -2.63 | Potential Upside | 1.70 | Standard Deviation | 1.21 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vertex Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Vertex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Vertex Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Vertex Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Massachusetts Financial Services Company | 2023-12-31 | 3.6 M | Capital Research Global Investors | 2023-12-31 | 3.6 M | Loomis, Sayles & Company Lp | 2023-12-31 | 3.1 M | Norges Bank | 2023-12-31 | 3 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 3 M | Goldman Sachs Group Inc | 2023-12-31 | 3 M | Amundi | 2023-12-31 | 2.7 M | Northern Trust Corp | 2023-12-31 | 2.7 M | Ubs Asset Mgmt Americas Inc | 2023-12-31 | 2.6 M | Vanguard Group Inc | 2023-12-31 | 22.3 M | Blackrock Inc | 2023-12-31 | 21.9 M |
Vertex Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 462.4M | 2.9B | 811.2M | 3.7B | (139.7M) | (132.7M) | |
| Free Cash Flow | 1.5B | 3.0B | 2.4B | 3.9B | 3.3B | 3.4B | |
| Depreciation | 106.9M | 109.5M | 125.6M | 148.3M | 181.3M | 190.4M | |
| Capital Expenditures | 75.5M | 259.8M | 235M | 204.7M | 258.4M | 271.3M | |
| Net Income | 1.2B | 2.7B | 2.3B | 3.3B | 3.6B | 3.8B | |
| End Period Cash Flow | 3.1B | 6.0B | 6.8B | 10.5B | 10.4B | 10.9B | |
| Other Non Cash Items | (176.2M) | (220.0M) | (5.8M) | 103.4M | (42.6M) | (40.5M) | |
| Change To Inventory | (64.0M) | (132.0M) | (92.8M) | (136.4M) | (322.9M) | (306.8M) | |
| Dividends Paid | 20.8M | 10.0M | 264.9M | 102M | 117.3M | 123.2M | |
| Investments | 33.7M | 378.5M | (28.9M) | 227.3M | (2.1B) | (2.0B) | |
| Change Receivables | (225.6M) | (223.4M) | (274.7M) | (358.6M) | (322.7M) | (306.6M) | |
| Net Borrowings | (35.0M) | (29.0M) | (24.4M) | (85.5M) | (77.0M) | (73.1M) | |
| Change To Netincome | 381.9M | 521.4M | 452.7M | 445.6M | 512.4M | 437.4M |
Vertex Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vertex Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vertex Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vertex stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.18 | |
β | Beta against NYSE Composite | 0.81 | |
σ | Overall volatility | 1.18 | |
Ir | Information ratio | -0.16 |
Vertex Pharmaceuticals Volatility Alert
Vertex Pharmaceuticals exhibits very low volatility with skewness of -0.34 and kurtosis of 0.37. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Vertex Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Vertex Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Vertex Pharmaceuticals Implied Volatility
Vertex Pharmaceuticals' implied volatility exposes the market's sentiment of Vertex Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Vertex Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Vertex Pharmaceuticals stock will not fluctuate a lot when Vertex Pharmaceuticals' options are near their expiration.
Vertex Pharmaceuticals Fundamentals Vs Peers
Comparing Vertex Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vertex Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Vertex Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vertex Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vertex Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vertex Pharmaceuticals to competition |
| Fundamentals | Vertex Pharmaceuticals | Peer Average |
| Return On Equity | 0.23 | -0.31 |
| Return On Asset | 0.13 | -0.14 |
| Profit Margin | 0.37 % | (1.27) % |
| Operating Margin | 0.38 % | (5.51) % |
| Current Valuation | 94.18 B | 16.62 B |
| Shares Outstanding | 258.46 M | 571.82 M |
| Shares Owned By Insiders | 0.11 % | 10.09 % |
| Shares Owned By Institutions | 97.29 % | 39.21 % |
| Number Of Shares Shorted | 3.98 M | 4.71 M |
| Price To Earning | 24.57 X | 28.72 X |
| Price To Book | 5.83 X | 9.51 X |
| Price To Sales | 10.38 X | 11.42 X |
| Revenue | 9.84 B | 9.43 B |
| Gross Profit | 5.32 B | 27.38 B |
| EBITDA | 3.93 B | 3.9 B |
| Net Income | 3.62 B | 570.98 M |
| Cash And Equivalents | 9.77 B | 2.7 B |
| Cash Per Share | 38.06 X | 5.01 X |
| Total Debt | 808.4 M | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 4.70 X | 2.16 X |
| Book Value Per Share | 68.22 X | 1.93 K |
| Cash Flow From Operations | 3.54 B | 971.22 M |
| Short Ratio | 3.84 X | 4.00 X |
| Earnings Per Share | 13.88 X | 3.12 X |
| Price To Earnings To Growth | 0.53 X | 4.89 X |
| Target Price | 466.14 | |
| Number Of Employees | 5.4 K | 18.84 K |
| Beta | 0.37 | -0.15 |
| Market Capitalization | 104.65 B | 19.03 B |
| Total Asset | 22.73 B | 29.47 B |
| Retained Earnings | 10.14 B | 9.33 B |
| Working Capital | 10.6 B | 1.48 B |
Note: Sale by Charles Wagner of 3000 shares of Vertex Pharmaceuticals [view details]
Vertex Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vertex . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.0147 | |||
| Daily Balance Of Power | (0.69) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 403.75 | |||
| Day Typical Price | 402.75 | |||
| Market Facilitation Index | 5.98 | |||
| Price Action Indicator | (5.07) | |||
| Period Momentum Indicator | (4.15) |
About Vertex Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Vertex Pharmaceuticals? Buying financial instruments such as Vertex Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 556.7M | 561M | 808.4M | 848.8M | Total Assets | 13.4B | 18.2B | 22.7B | 23.9B |
Use Investing Ideas to Build Portfolios
In addition to having Vertex Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Advertising Thematic Idea Now
Advertising
Companies specializing in advertising, marketing and advertising services. The Advertising theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Advertising Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Vertex Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.88 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.